Related Experiment Video
Updated: Apr 17, 2026
In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
Bestatin induces specific changes in Trypanosoma cruzi dipeptide pool
Andrea Trochine1, Darren J Creek2, Paula Faral-Tello3
1Unidad de Biología Molecular, Institut Pasteur de Montevideo, Montevideo, Uruguay Laboratorio de Microbiología Aplicada y Biotecnología, Instituto de Investigaciones en Biodiversidad y Medio Ambiente (CONICET), Universidad Nacional del Comahue, San Carlos de Bariloche, Río Negro, Argentina atrochine@gmail.com robello@pasteur.edu.uy.
Bestatin treatment confirmed inhibition of key enzymes in Trypanosoma cruzi, a parasite causing Chagas disease. This study monitored metabolite changes, revealing increased dipeptides and validating peptidases as potential drug targets for new antichagasic therapies.
Area of Science:
- Biochemistry
- Parasitology
- Drug Discovery
Background:
- Proteases and peptidases are crucial enzymes in Trypanosoma cruzi, making them attractive targets for developing antichagasic chemotherapy.
- Identifying effective inhibitors of these enzymes is essential for combating Chagas disease.
Purpose of the Study:
- To investigate the effects of bestatin, a metalloaminopeptidase inhibitor, on low-mass metabolites in Trypanosoma cruzi epimastigotes.
- To confirm the in situ inhibition of leucine aminopeptidase of T. cruzi (LAPTc) and other peptidases by bestatin.
Main Methods:
- Treatment of T. cruzi epimastigotes with bestatin.
- Monitoring and analysis of changes in low-mass metabolites using techniques like mass spectrometry (implied).
Main Results:
- Treatment with bestatin led to a significant increase in multiple dipeptides within the epimastigotes.
- The observed dipeptide accumulation confirmed the effective inhibition of leucine aminopeptidase of T. cruzi (LAPTc).
- Evidence suggests that bestatin also inhibits other peptidase activities in T. cruzi.
Conclusions:
- Bestatin effectively inhibits key peptidases, including LAPTc, in Trypanosoma cruzi.
- The study validates peptidases as promising targets for the development of novel antichagasic drugs.
- Metabolite profiling can be a valuable tool for assessing drug efficacy and mechanism of action in parasitic infections.
